A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita (VAPAUS)
Diseases of the Integumentary System | Genetics - Adult
What is the purpose of this trial?
This study evaluates the safety and efficacy of QTORIN 3.9% rapamycin anhydrous gel in the treatment of adults with Pachyonychia Congenita. This study includes a screening period, baseline period and 6-month treatment period.
- Ages18 years and older
- Trial withPalvella Therapeutics, Inc.
- Start Date01/14/2022
- End Date06/30/2023
- Last Updated02/02/2022
- Study HIC#2000031568